MorphoSys AG (MOR.DE) XETRA

Currency In EUR

Key Executives

Name	Title	Pay	Year Born
Arkadius Pichota	Chief Executive Officer	0	N/A
Marlies Sproll	Special Adviser to the Chief Executive Officer	0	1958
Charlotte Lohmann	Chief Legal and Human Resources Officer & Member of Management Board	474,100	1970
Harald Watzka	Head of Alliance Management	0	N/A
Klaus De Wall	Head of Accounting & Tax	0	N/A
Barbara Krebs-Pohl	Chief Business Officer	0	N/A
Günter Wellnhofer	Head of Technical Operations	0	N/A
Julia Neugebauer	Head of Investor Relations	0	N/A
Tim Demuth	Chief Research & Development Officer	0	1974
Luisa Ciccarelli	SVice President & Global Head of Technical Operations	0	N/A
Yen Ching Chua	Head of Clinical Operations	0	N/A
Lukas Gilgen	Chief Financial Officer	0	N/A
Thomas Biegi	Senior Vice President & Head of Corporate Affairs	0	N/A
Kathrin Tissot	Head of Business Team	0	N/A
Margit Urban	Head of Discovery Alliances & Technologies	0	N/A

Name

Title

Pay

Year Born

Arkadius Pichota

Chief Executive Officer

N/A

Marlies Sproll

Special Adviser to the Chief Executive Officer

1958

Charlotte Lohmann

Chief Legal and Human Resources Officer & Member of Management Board

474,100

1970

Harald Watzka

Head of Alliance Management

N/A

Klaus De Wall

Head of Accounting & Tax

N/A

Barbara Krebs-Pohl

Chief Business Officer

N/A

Günter Wellnhofer

Head of Technical Operations

N/A

Julia Neugebauer

Head of Investor Relations

N/A

Tim Demuth

Chief Research & Development Officer

1974

Luisa Ciccarelli

SVice President & Global Head of Technical Operations

N/A

Yen Ching Chua

Head of Clinical Operations

N/A

Lukas Gilgen

Chief Financial Officer

N/A

Thomas Biegi

Senior Vice President & Head of Corporate Affairs

N/A

Kathrin Tissot

Head of Business Team

N/A

Margit Urban

Head of Discovery Alliances & Technologies

N/A

Description

MorphoSys AG operates as a commercial-stage biopharmaceutical firm, concentrating on the discovery, development, and marketing of therapeutic antibodies. Its primary focus is on addressing cancer and autoimmune conditions, particularly within the United States. The company's lead commercial product is Tafasitamab, an antibody used to treat various B-cell cancers, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. MorphoSys's development pipeline includes several promising candidates: Pelabresib, a small molecule, is currently in Phase II trials for myelofibrosis. Felzartamab, an antibody targeting CD38, is undergoing Phase I/II clinical evaluation for anti-PLA2R-positive membranous nephropathy, an autoimmune disorder. Another small molecule, CPI-0209, is in Phase I/II studies, engineered to boost anti-tumor effects by inhibiting EZH2. Through collaborations with pharmaceutical partners, MorphoSys also contributes to the development of other antibody treatments, such as: Gantenerumab for Alzheimer's disease. Otilimab for rheumatoid arthritis. Tremfya, addressing psoriasis, psoriatic arthritis, and palmoplantar pustulosis. MOR210/TJ210 for immuno-oncology and autoimmune conditions. The company maintains a variety of strategic alliances and agreements. These include a regional licensing deal with I-Mab Biopharma for the development and commercialization of felzartamab across China, Taiwan, Hong Kong, and Macau. MorphoSys has a strategic alliance with LEO Pharma and a joint collaboration and licensing agreement with Incyte Corporation for the development and commercialization of its investigational compound, tafasitamab. Furthermore, a clinical collaboration exists with Incyte Corporation and Xencor, Inc. to investigate a combination of tafasitamab, plamotamab, and lenalidomide for patients with relapsed or refractory diffuse large B-cell lymphoma and relapsed or refractory follicular lymphoma. Established in 1992, MorphoSys AG is headquartered in Planegg, Germany.